Literature DB >> 7484057

CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.

E Eldrup1, P Mogensen, J Jacobsen, H Pakkenberg, N J Christensen.   

Abstract

OBJECTIVE: To investigate endogenous cerebrospinal fluid catecholamines in Parkinson's disease.
MATERIAL AND METHODS: Basal concentrations of free norepinephrine (NE), dopamine (DA), epinephrine (E), 3,4-dihydroxyphenylacetic acid (DOPAC) and 3,4-dihydroxyphenylalanine (DOPA) in cerebrospinal fluid (csf) and plasma were measured using reverse-phase HPLC with electrochemical detection in 16 patients with Parkinson's disease and 21 control patients with low back pain.
RESULTS: Parkinsonian patients had significantly decreased values of csf NE and DOPAC, the strong relationship between plasma and csf NE was disrupted and neither was there any age related increase of plasma NE. In l-DOPA treated patients plasma DA and DOPA concentrations were raised and csf DOPAC values were inversely related to severity of disease (Hoehn and Yahr score). Csf E concentrations were also reduced in parkinsonian patients whereas csf DA concentrations were unchanged. Csf DOPA concentrations were insignificantly decreased in parkinsonian patients.
CONCLUSIONS: These results point towards a diffuse neuronal dysfunction in Parkinson's disease and indicate that lumbar csf NE and csf DOPAC are of central nervous origin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7484057     DOI: 10.1111/j.1600-0404.1995.tb01023.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  24 in total

1.  Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  S Engelborghs; B Marescau; P P De Deyn
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

2.  Cerebrospinal fluid catecholamine levels in Japanese encephalitis patients with movement disorders.

Authors:  U K Misra; J Kalita; S Pandey; V K Khanna; G Nagesh Babu
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

Review 3.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

4.  Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi; Deborah C Mash
Journal:  Parkinsonism Relat Disord       Date:  2015-03-20       Impact factor: 4.891

5.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

6.  Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion.

Authors:  Marco Leyton; Marije aan het Rot; Linda Booij; Glen B Baker; Simon N Young; Chawki Benkelfat
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

7.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

8.  Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.

Authors:  David S Goldstein; Courtney Holmes; Oladi Bentho; Takuya Sato; Jeffrey Moak; Yehonatan Sharabi; Richard Imrich; Shielah Conant; Basil A Eldadah
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

Review 9.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

10.  Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.

Authors:  David S Goldstein; Patti Sullivan; Courtney Holmes; Guillaume Lamotte; Abhishek Lenka; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2021-05-21       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.